BCLI Brainstorm Cell Therapeutics Inc.

4.16
+0.02  (+1%)
Previous Close 4.14
Open 4.12
Price To Book -13.88
Market Cap 94,104,044
Shares 22,606,492
Volume 86,411
Short Ratio
Av. Daily Volume 121,862
Stock charts supplied by TradingView

NewsSee all news

  1. BrainStorm Cell Therapeutic's COO and CMO, Dr. Ralph Kern, to Present at the 10th Annual California ALS Research Summit

    NEW YORK and LOS ANGELES, Jan. 21, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that

  2. BrainStorm Cell Therapeutics to Present at the 2020 Biotech Showcase and 3rd Annual Neuroscience Innovation Forum at JPM Week

    NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits,

  3. NurOwn® Data Safety Monitoring Board Recommends MS Phase 2 Clinical Trial Continue

    NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that the clinical trial

  4. BrainStorm Issues 2019 Letter to Shareholders

    NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapeutics for neurodegenerative diseases, today issued a Letter to Shareholders.

  5. BrainStorm Selected as Buzz of BIO 2020 Winner

    NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 top-line data due 4Q 2020.
NurOwn
Amytrophic lateral sclerosis (ALS)
Phase 2 top-line data due mid-2020. Noted December 19, 2019 that the DSMB said following interim analysis that the trial should continue as planned.
NurOwn
Progressive Multiple Sclerosis

Latest News

  1. BrainStorm Cell Therapeutic's COO and CMO, Dr. Ralph Kern, to Present at the 10th Annual California ALS Research Summit

    NEW YORK and LOS ANGELES, Jan. 21, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that

  2. BrainStorm Cell Therapeutics to Present at the 2020 Biotech Showcase and 3rd Annual Neuroscience Innovation Forum at JPM Week

    NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits,

  3. NurOwn® Data Safety Monitoring Board Recommends MS Phase 2 Clinical Trial Continue

    NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that the clinical trial

  4. BrainStorm Issues 2019 Letter to Shareholders

    NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapeutics for neurodegenerative diseases, today issued a Letter to Shareholders.

  5. BrainStorm Selected as Buzz of BIO 2020 Winner

    NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases,

  6. BrainStorm Cell Therapeutics to make scientific presentations at the 30th International Symposium on ALS/MND

    NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases,

  7. BrainStorm Announces the Mount Sinai Medical Center as a Progressive MS Phase 2 Clinical Trial Site

    NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today

  8. BrainStorm Cell Therapeutics Announces Publication of NurOwn® ALS Phase 2 Randomized Clinical Trial Data in Neurology

    A single transplantation of MSC-NTF cells (NurOwn®) in ALS clinical trial participants met the primary safety endpoint and demonstrated promising stabilization of ALS disease progression of up to 12-16 weeks in a

  9. BrainStorm Cell Therapeutics Announces Research Grant Award From the National Multiple Sclerosis Society

    NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that the Company has

  10. BrainStorm Announces Financial Results for the Third Quarter of 2019 and Provides a Corporate Update

    Conference Call and Webcast Today at 8:00 a.m. Eastern Time Highlights Include: ALS Phase 3 Clinical Trial Fully Enrolled, Data Safety Monitoring Board Recommends ALS Phase 3 Clinical Trial Continue,

  11. BrainStorm Announces Grant of a New Japanese Patent for NurOwn®

    NEW YORK, Nov. 13, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the Japan Patent

  12. BrainStorm Cell Therapeutics to Announce Third Quarter Financial Results and Provide a Comprehensive Corporate Update

    NEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Company will hold

  13. NurOwn® Data Safety Monitoring Board Recommends ALS Phase 3 Clinical Trial Continue

    NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Phase 3 clinical

  14. BrainStorm Cell Therapeutics Presentations at Neuromuscular Drug Development Summit

    NEW YORK, Oct. 23, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases,

  15. BrainStorm's NurOwn® Phase 3 ALS Clinical Trial Now Fully Enrolled

    NEW YORK, Oct. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it has fully enrolled

  16. BrainStorm Announces Notice of US Patent Allowance for NurOwn® Cellular Therapeutic Technology Platform

    NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the United States

  17. BrainStorm Cell Therapeutics to Present NurOwn® Phase 2 Biomarker Data at North East Amyotrophic Lateral Sclerosis (NEALS) 18th Annual Meeting

    NEW YORK, Oct. 02, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases

  18. BrainStorm Cell Therapeutics Announces Support for FDA Guidelines on ALS Drug Development

    NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases

  19. BrainStorm Strengthens Senior Executive Management Team with the Appointment of Preetam Shah, Ph.D., M.B.A., as Chief Financial Officer

    NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that Preetam Shah, Ph.D.,

  20. BrainStorm Cell Therapeutics to Present Late Breaking News ePoster at the 35th ECTRIMS Congress

    NEW YORK, Sept. 06, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases,